Akin Gump is pleased to announce that Nathan A. Brown, former U.S. Food and Drug Administration (FDA) lawyer and Senate Health, Education, Labor and Pensions (HELP) Committee advisor, has joined the firm as a health care and life sciences partner in the firm’s Washington, DC office.
At Akin Gump, Mr. Brown will provide regulatory, compliance and policy advice to health industry participants with regard to drugs, biologics and medical devices as well as cosmetics and food products regulated by the FDA. Prior to joining the firm, he served in several prominent roles with the FDA. Most recently, he was detailed to serve as health policy advisor to the Senate HELP Committee to cover FDA issues.
Mr. Brown has substantial experience in drug legislation matters including, on behalf of HELP Committee Chairman Tom Harkin, playing a lead role negotiating and drafting the Drug Quality and Security Act of 2013 – which addresses compounded drugs and establishes a nationwide track and trace system for the pharmaceutical supply chain – as well as in coordinating passage of the Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013.
Mr. Brown has also advised FDA’s Center for Devices and Radiological Health on a wide range of matters, including software and health IT regulation, device review program reform, third-party review, laboratory-developed tests and appeals issues. He served as counsel on the medical device user fee reauthorization negotiation team (“MDUFA 3”) and represented the FDA in providing assistance to Congress on device reform for the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).